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 CURRENTOPINION Premise and promise of mesenchymal stem
cell-based therapies in clinical vascularized
composite allotransplantation
Riccardo Schweizera, Vijay S. Gorantlab,c, and Jan A. Plocka,b
Purpose of review
Over the past decade, clinical vascularized composite allotransplantation (VCA) has enabled functional
and quality of life restoration in a wide range of indications secondary to devastating tissue loss. However,
the spectre of toxicity and long-term complications of chronic immunosuppression has curtailed the
momentum of VCA. This study summarizes the literature evidence behind successful mesenchymal stem cell
(MSC)-based cell therapies highlighting their multipronged immunomodulatory, restorative and regenerative
characteristics with special emphasis towards VCA applications.
Recent findings
Experimental and clinical studies in solid organs and VCA have confirmed that MSCs facilitate
immunosuppression-free allograft survival or tolerance, stimulate peripheral nerve regeneration, attenuate
ischaemia-reperfusion injury, and improve tissue healing after surgery. It has been hypothesized that MSC-
induced long-term operational tolerance in experimental VCA is mediated by induction of mixed donor-
specific chimerism and regulatory T-cell mechanisms. All these characteristics of MSCs could thus help
expand the scope and clinical feasibility of VCA.
Summary
Cellular therapies, especially those focusing on MSCs, are emerging in solid organ transplantation
including VCA. Although some clinical trials have begun to assess the effects of MSCs in solid organ
transplantation, much scientific domain remains uncharted, especially for VCA.
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INTRODUCTION
Until recently, few reconstructive options were
available for patients with disfiguring and func-
tional devastating tissue defects secondary to
trauma, oncological resection or congenital malfor-
mation. Over the past 2 decades, the technical,
immunologic and functional feasibility of vascular-
ized composite allotransplantation (VCA) as an
alternative restorative option has been established
in such indications. Overall, intermediate and long-
term graft and patient outcomes have been encour-
aging for extremity and facial VCA with improved
quality of life [1,2]. The prospect of allograft depend-
ency on chronic, lifelong drug immunosuppression,
with the risk of infectious, metabolic or neoplastic
complications remains a significant hurdle for
clinical advancement of VCA [3]. Development of
safe and effective protocols consistent with immu-
nosuppression-free graft survival is an immediate
priority in nonlife saving transplants such as VCA.
Unlike other solid organs, optimal functional
recovery is a prerequisite in VCA, which relies on
timely and proper sensory and motor nerve regen-
eration and reintegration for overall success. With-
out it, a VCA would be deemed a failure, increasing
the risk/benefit ratio of long-term immunosuppres-
sion and questioning the ethical equipoise of VCA.
Also unlike solid organs, VCA are extraneous grafts
requiring matching for size, skin colour, tone and
anatomical congruity. These requirements limit the
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available donor-pool and may require donor grafts
to be shared over long distances, with increased cold
ischaemia times and possible risks of worse ischae-
mia-reperfusion (I/R) injury. All these constraints
jeopardize the life-enhancing benefits of VCA pro-
cedures. Research efforts striving to overcome these
obstacles have included the use of cellular therapies
such as those incorporatingmesenchymal stem cells
(MSCs), given their multifaceted effects ranging
from immunomodulation and tissue healing to neu-
roregeneration andmitigation of I/R injury [4,5
&&
,6].
Herein we provide a brief overview of the prem-
ise and potential of MSC therapy in addressing
different therapeutic goals inherent to VCA, focus-
ing on their broad-based beneficial effects and
recently emerging outcomes of experimental studies
and clinical trials in solid organ transplantation
(SOT) and VCA.
MESENCHYMAL STEM CELLS
A broad selection of different cell types could play a
relevant role in cell-based therapy for VCA. Regu-
latory T cells (Tregs) [7], dendritic cells [8,9], MSCs,
whole bone marrow (WBM) and other cells
have been evaluated in SOT and VCA. MSCs are
undifferentiated, multipotent, self-renewing cells,
widespread throughout the body, possessing angio-
genic, immunomodulatory, pro-neurogenic and
antiapoptotic functionality and capable of mesen-
chymal tissue differentiation, for example bone,
muscle, cartilage, endothelium and fat [10,11].
Together, these characteristics have relevance and
impact in VCA. MSCs have been isolated from var-
ious tissues including, bone marrow mesenchymal
stromal cells (BM-MSCs) and subcutaneous fat
tissue (adipose-derived stem cells; ASCs). The latter
source is appealing due to ease of procurement, low
morbidity and high cell yields. ASCs may also
have superior immunomodulatory potency [5
&&
],
as compared with bone marrow or other sources
of MSCs [5
&&
,6,12,13].
POTENTIAL OF MESENCHYMAL STEM
CELL THERAPIES IN CLINICAL
VASCULARIZED COMPOSITE
ALLOTRANSPLANTATION
Donor-cell chimerism
A multitude of experimental reports in small and
large animals have demonstrated prolonged allog-
raft survival in VCA either after single or repetitive
MSC administration [14
&&
,15,16,17
&
,18
&
,19–24].
MSCs seem to favour the establishment of mixed
donor-cell chimerism in VCA recipients [25–27].
Cetrulo et al. found that hematopoietic cell infu-
sions induced donor-specific tolerance to myocuta-
neous flap VCA in a large animal model with
persistent donor-cell chimerism over weeks in a
manner similar to VCA transplantation in estab-
lished chimeras [28]. This is of important transla-
tional value for reconstructive transplantation, as
VCA donors are usually brain dead and all tissues
have to be procured simultaneously. Although some
authors successfully achieved long-term tolerance
after single infusion of WBM even without persist-
ent peripheral donor-cell chimerism [25], other
reports suggest a positive effect of preestablished
and stable donor-specific chimerism on composite
allograft survival across major histocompatibility
mismatches [16]. Thus, although donor-cell chimer-
ism is regarded as key step for long-term tolerance,
it is not yet clear if sustained chimerism is actually
required for graft survival. Interestingly, in a recent
report allografts survived after loss of donor-specific
chimerism and were not rejected after reconstitu-
tion with host hematopoietic cells [29].
Modulation of immune response
The immunomodulatory and anti-inflammatory
properties of MSCs hold promise as a therapeutic
approach for induction of allograft tolerance, even
though it is not clear yet if MSCs alone are able to
induce a solid long-term transplant tolerance or if
cellular therapies have to be supported at least in
part by other cell types and/or drug-based immuno-
suppressive regimens. As far as it concerns VCA,
there is only a small body of evidence for the mod-
ulatory effects ofMSCs. Recent reports point out to a
beneficial immunomodulatory effect of both BM-
MSCs and ASCs on the survival rate of rat hind limbs
KEY POINTS
 Clinical vascularized composite allotransplantation
is an expanding therapeutic option for functional
restoration after devastating tissue loss, however,
hampered by the need for long-
term immunosuppression.
 Cellular therapies including mesenchymal stem cells
show promise in establishing long-term operational
allograft tolerance and obviate to the hurdles of
drug-immunosuppression.
 Mesenchymal stem cells show additional beneficial
effects (peripheral nerve regeneration, attenuation of
I/R injury, facilitation of tissue healing after surgery)
that additionally expand clinical feasibility of VCA.
Mesenchymal stem cell-based therapies in VCA Schweizer et al.
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while coupled to a short initial course of calcineurin
inhibitors [17
&
,18
&
].
There are several putativemechanisms by which
MSCs can exert their effect to dampen the immune
response to alloantigens, all summarized recently by
Kim et al. (reviewed in [30]).
One mechanism under intensive investigation
is the MSC-mediated Treg recruitment and expan-
sion in both peripheral blood and allograft
[17
&
,22,31]. In contrast, however, Jiang et al. found
that Treg depletion in transplant recipients did not
compromise BM-MSC ability to suppress allograft
rejection in murine heart transplant recipients [32].
Most of MSC’s immunosuppressive activity is
mediated through paracrine signalling, with the
MSC secretome playing a pivotal role and acting
on a variety of pathways including interaction
with T and B lymphocytes, as well as inhibition of
macrophages, monocytes and natural killer cells
among others.
Soluble factors involved are for example
indoleamine 2,3-dioxygenase, transforming growth
factor-b, nitric oxide, tumour necrosis factor-indu-
cible gene 6 protein and prostaglandins. Moreover,
cells of the immune system can shift from a pro-
inflammatory to an anti-inflammatory phenotype
under MSC influence.
Other than dampening the recipient’s imm
une reaction against allografts, through their sup-
pressive function MSCs offer the opportunity to
attenuate graft-versus-host disease (GvHD) as well
(reviewed in [33]), especially when given in conjunc-
tion with hematopoietic stem cell (HSC) or WBM,
where the risk of GvHD is increased.
Syngeneic, allogeneic and xenogeneic
mesenchymal stromal cells
It is important to distinguish between allogeneic,
syngeneic or even xenogeneic MSC sources. Donor-
derived (allogeneic) cells need to be procured at the
time of transplantation along with the graft and
either frozen down, further processed or placed in
culture and expanded for later administration.
Autologous (syngeneic) cells are readily available
from the host, can be freshly procured any time
and repetitively administered. Chen et al. reported
that a single injection of syngeneic ASCs along with
antilymphocyte serum and a short course of cyclo-
sporine A achieved rodent limb VCA survival in 66%
recipients [18
&
]. In comparison, studies using allo-
geneic MSCs reported a lower long-term survivor
rate [17
&
,20], suggesting that even if MSCs are
immunoprivileged (due to absence of MHC Class
II markers), autologous cells could have a higher
survival rate and better impact on the outcome. One
group recently used (xenogeneic) human ASCs
(hASC) to induce skin allograft tolerance in mice
[24]. hASC monotherapy accomplished only slight
improvements in graft survival. In contrast, combi-
nation of hASCs with murine WBM achieved 100%
long-term survival, suggesting rejection of the xen-
ogeneic ASCs. We recently reported that BM-MSCs
and ASCs are not substantially different in efficacy
in a rat osteomyocutaneous VCA model with a
short course of tacrolimus under an antilympho
cyte serum preconditioning regimen [17
&
]. Both
regimens successfully promoted immunosuppres-
sion-free long-term survival in around 50% of the
recipients with transient peripheral chimerism and
increased Treg levels. The in-vitro immunomodula-
tory function of ASCs was superior to that of BM-
MSCs.
Drug–mesenchymal stem cell interactions
Recent literature evidence reaffirms that an induc-
tion regimen or early short-course immunosuppres-
sion is probably essential for the success of tolerance
strategies [34,35]. Eggenhofer et al. reported accel-
erate rejection and worse outcomes after MSC
therapy without concomitant immunosuppression
[36]. Allogeneic mouse islets were prolonged after
MSCs in combination with CTLA-4-Ig co-stimu-
latory blockade but not with isolated MSC therapy
[37
&
]. Lee et al. reported that in the absence of
preconditioning, hASCs achieved only a discrete
prolongation of murine allogeneic skin grafts sur-
vival injection of conditioned medium prolonged
graft survival and reduced inflammatory tissue cyto-
kine levels, suggesting a paracrine mechanism [34].
In another study, repetitive administration
of omental rat ASCs over 3 days without adjunct
immunosuppression delayed skin graft rejection
without long-term tolerance, despite increased Treg
levels in skin specimens [35]. Similarly, Larocca et al.
found that allogeneic ASCs can prolong skin graft
survival and recruit Tregs into draining lymph nodes.
Of interest, in that study, allogeneic donor-matched
ASCs were more efficient than host-matched synge-
neic or third-party ASCs [38]. Nevertheless, the toxic
effect of concomitant conditioning and mainten-
ance drugs on MSC viability and function should
not be underestimated as supported by our recent
in-vitro findings [39]. Singh et al. reported that
sirolimus (rapamycin) is superior to tacrolimus in
preserving the Treg phenotype and FoxP3 expression
[40]. Given the in-vivo impact and relevance of such
toxicity, the timing, dosing and frequency of cellu-
lar therapies may need to be optimized and tailored
in the context of such induction regimens in order
to avoid collateral effects.
Composite tissue transplantation
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Supportive use of different cell types
The presence of active vascularized bone marrow in
certain VCA may benefit allograft survival [41]. It
remains unclear if systemic administration of a
similar amount of WBM would achieve similar
effects or if the donor-specific bone marrow niche
is a requirement that fosters the development of
robust and stable donor-cell chimerism. Treg induc-
tion and recruitment may be important for main-
tenance of peripheral tolerance and avoidance of
rejection. A recent report by Obermajer et al.
suggests direct T-cell conversion from Th1-T cells
to Tregs by MSC influence as a mechanism of Treg
induction [42]. A 2013 study revealed that Treg
injection (at lower doses than with WBM therapy)
along with vascularized bone marrow transplan-
tation achieved 90% graft acceptance and sustained
peripheral donor-cell chimerism without need for
cytoreduction [7]. In a canine VCA model, Mathes
et al. found that intragraft Treg levels were similar in
long-termVCA recipients regardless of bonemarrow
infusion. This was confirmed in vitro by increased
suppressor function on alloantigen-stimulated
T-cell proliferation by Tregs derived from long-term
acceptors [14
&&
]. An interesting potential approach
could be the use of purified MSCs along with HSCs,
which have been shown to enhance engraftment
and reconstitution [43]. Early clinical protocols
combining ASCs and HSCs for tolerance induction
in kidney transplantation show promising results
[5
&&
]. However, further experimental studies are
needed to elucidate if this is a valid option for VCA.
Therapy of acute and chronic rejection
Studies investigating the potential ability of auto
logous, allogeneic, fresh or frozen MSCs for attenu-
ation and therapy of rejection in allotransplantation
are scant. The characteristics of MSC in promoting
Treg recruitment, anti-inflammatory function and
paracrine secretion of anti-inflammatory factors
may all benefit their role in prevention or manage
ment of acute or chronic rejection. However,
without substantive research, these purported
advantages remain speculative in VCA.
Routes of administration
The mode of MSC administration in VCA is of
relevance as most cells get entrapped in lungs and
filtering organs such as liver and spleen after intra-
venous injection [44]. Albeit the simplicity and ease
of intravenous injection, barring potential embolic
events, it is still under debate if MSCs need to home
and engraft locally into the target tissue to exert
their therapeutic effect or if they can exert their
immunomodulatory effects from distance in a para-
crine fashion. According to a recent report early,
high-dose, intravenous MSC administration should
be preferred [32]. Alternative approaches represent
the direct intraarterial injection to improve target
cell-load [45], local scaffold-assisted delivery to
favour cell viability and proliferation at the target
site and diminish spreading of cells to have high
loco-regional effects [46] or cell encapsulation to
allow for systemic administration but with
improved cell survival through a protective ‘cell
coating’ [47,48]. Despite all these approaches, the
ideal therapeutic dosage of MSCs for a given appli-
cation remains unknown.
Nerve regeneration, protection from
ischaemia-reperfusion injury, wound
and bone healing
The versatility of MSC therapy potentially extends
beyond tolerance induction and modulation of
immune responses after VCA. There are many other
supplementary benefits ofMSCs of relevance to VCA
outcomes. Most notable is peripheral nerve regen-
eration, which is critical in VCA, where unlike in
SOT, overall functional restoration relies on motor
and sensory recovery in the graft. Multiple studies
confirm that bone marrow and ASCs facilitate
functional recovery after peripheral nerve injury
[49–51]. Intravenous MSCs home to injured sciatic
nerves and improve functional recovery after tran-
section [51]. ASCs have been shown to exert their
beneficial effects through paracrine neurotrophic
and angiogenic effects, a mechanism that is still
debated [49]. MSC therapy aiming at enhancing
nerve regeneration could necessitate repetitive
treatments due to the slow nature of the regener-
ation process. I/R injury is linked with acute and
chronic rejection and worse long-term outcomes in
transplantation [52]. The ability of MSCs in mitigat-
ing reperfusion injury has been attributed to para-
crine anti-inflammatory effects [53], with reduction
in I/R injury in skin flaps [54,55] and in renal I/R
injury [56,57]. In the latter study, MSCs but not
conditioned medium were able to ameliorate I/R
injured kidneys, which is in line with own findings
where BM-MSCs but not conditioned medium were
anti-inflammatory on activated endothelium in a
critically ischaemic skin flap [53]. Effective mitiga-
tion of I/R injury after cold ischaemia could promote
VCA allocation over larger geographical distances,
decreasing ischaemia-related time constraints and
expanding VCA donor-pool. MSCs also enhance
bone healing, which is of utmost relevance for
(bony) face and extremity transplantation [58].
BM-MSCs have been shown to improve healing of
Mesenchymal stem cell-based therapies in VCA Schweizer et al.
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critical calvarial defects after systemic infusion
despite a low local cell engraftment rate [59]. Finally,
the antiscarring, antiapoptotic and angiogenic
properties of MSCs could all potentially contribute
to improved wound healing and overall outcomes.
Mesenchymal stem cell therapies for clinical
solid organ transplantation and bone-marrow
transplantation
First clinical trials have begun evaluating the use of
MSCs for induction of allograft tolerance in SOT,
especially in kidney transplantation [5
&&
,60–63].
MSC administration prior and after kidney trans-
plantation seems to be safe and efficacious in reduc-
ing the dose of maintenance drugs [60,62]. In a
very recent case series, pre- and one post-transpl
ant administration of autologous MSCs expanded
peripheral Tregs and decreased T-cell proliferation
retaining graft function in kidney transplant
patients [63]. An interesting approach by Vanikar
et al. included combined ASC and HSC therapy prior
to transplantation under a nonmyeloablative con-
ditioning regimen for immunomodulation in kid-
ney transplantation showing a 94.7% 5-year survival
comparedwith 84% in the control group [5
&&
]. Other
than tolerance induction, cellular therapy of
GvHD is another aspect under clinical investigation
[64,65]. In cases of steroid-refractory GvHD in HSC-
transplanted patients, repetitive third-party BM-
MSC infusions over 3 weeks achieved more than
70% responders with cessation of GvHD symptoms
[66], which is in line with a very recent report [64].
Fortunately, human freeze-thawed BM-MSCs have
recently been found to retain their immunosuppres-
sive activity against GvHD, potentially allowing for
third party off-the-shelf cell products for therapy of
such conditions [67].
The Pittsburgh Protocol is the first cell therapy
protocol used in upper extremity transplantation
incorporating WBM that has facilitated monother-
apymaintenance of VCA in compliant patients [13].
Other groups have administered WBM in clinical
VCA as part of a multidrug immunosuppression
protocol [6]. However, combination cellular thera-
pies of WBM, HSCs andMSCs remain unexplored. A
combined approach could bring promising benefits
in VCA as well, underscored by recent evidence
suggesting improved engraftment of HSC co-admin-
istered with MSCs [68]. Experimental data for other
cell products such as ASCs in VCA are also scarce.
CONCLUSION
Proof of principle has been established for cellular
therapies usingMSCs in both SOT and VCA. Clinical
trials have investigated MSC therapy for renal trans-
plantation. Although there are clinical reports of
WBM infusion after hand and face transplants
[6,69], there are no reported clinical attempts
incorporating isolated or enriched MSCs in VCA.
Multiple studies in the literature reinforce the
promise and potential for MSCs in prolonging allog-
raft survival and other aspects (promoting nerve
regeneration, protecting from I/R injury) that could
improve overall graft outcomes after VCA. Many
questions do persist, such as themechanisms under-
lying tolerance or graft acceptance, optimizing the
conditioning regimen in the context of induction
immunosuppression, the dosing, timing, route and
frequency of cell administration and the use of other
cell types such as ASCs in conjunction with MSCs
to improve synergistic, complementary or additive
efficacy after VCA.
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